GH/IGF system, cirrhosis and liver transplantation.
The GH-related effects are primarily mediated by insulin-like growth factor I (IGF-I), a peptide hormone almost completely produced by the liver. Liver cirrhosis is usually accompanied by a fall in protein turnover. Furthermore, an important consequence of chronic liver disease (CLD) is growth hormone/insulin-like growth factor (GH/IGF) axis modification and growth failure. Nutritional status also suffers in this condition, and IGF-I has been proposed as a marker of hepatocellular dysfunction, malnutrition and survival. CLD is characterised by alterations of various clinical biochemistry laboratory parameters. Aminotransferases, bilirubin, plasma proteins, together with prothrombin time and gamma globulins, are usually examined for laboratory diagnostic and/or monitoring purposes. These traditional parameters are also used in the perioperative liver transplantation, but an early signal of graft functioning has still not been established. The aim of the present work is a review of the possibility offered by the clinical biochemistry laboratory GH/IGF investigation in the outcome of liver transplantation.
De Palo
E F
EF
Clinical Biochemistry, Department of Medical Diagnostic Sciences, University of Padova, Padua, Italy.
Bassanello
M
M
Lancerin
F
F
Spinella
P
P
Gatti
R
R
D'Amico
D
D
Cillo
U
U
D013006:Growth Hormone / Q000502:physiology*; D006801:Humans; D008103:Liver Cirrhosis / Q000503:physiopathology* / Q000601:surgery*; D016031:Liver Transplantation; D013002:Somatomedins / Q000502:physiology*
D013002:Somatomedins; D013006:Growth Hormone